Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy

Biomaterials

Volumn 102, Issue , 2016, Pages 187-197

  Zhao, Xiao ^a,b   Yang, Keni ^b   Zhao, Ruifang ^b   Ji, Tianjiao ^b   Wang, Xiuchao ^a   Yang, Xiao ^b   Zhang, Yinlong ^b   Cheng, Keman ^b   Liu, Shaoli ^b   Hao, Jihui ^a   Ren, He ^a   Leong, Kam W ^c   Nie, Guangjun ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^c Department of Earth and Environmental Sciences   (United States)

Author keywords

Dendritic cells; Gemcitabine; Immunogenic cell death; Nanocarriers; Oxaliplatin; Pancreatic cancer

Indexed keywords

CELL DEATH; CYTOLOGY; DISEASES; ENZYME INHIBITION; IMMUNE SYSTEM; LYMPHOCYTES; MAMMALS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; T-CELLS; TUMORS;

DENDRITIC CELLS; GEMCITABINE; NANO-CARRIERS; OXALIPLATIN; PANCREATIC CANCERS;

CELLS;

BETA ACTIN; CASPASE 3; CASPASE 7; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; HIGH MOBILITY GROUP B1 PROTEIN; NANOCARRIER; OXALIPLATIN; ANTINEOPLASTIC AGENT; GAMMA INTERFERON; NANOPARTICLE; PLATINUM COMPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CONFOCAL MICROSCOPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; MOUSE; NANOENCAPSULATION; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; PANCREAS; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; MICE, INBRED C57BL; NANOPARTICLES; ORGANOPLATINUM COMPOUNDS; PANCREAS; PANCREATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84975822161     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.06.032     Document Type: Article

References (54)

1. [1] Thakor, A.S., Gambhir, S.S., Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J. Clin. 63 (2013), 395–418.
2. [2] Sun, T., Zhang, Y.S., Pang, B., Hyun, D.C., Yang, M., Xia, Y., Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. Engl. 53 (2014), 12320–12364.
3. [3] Li, F., Zhao, X., Wang, H., Zhao, R.F., Ji, T.J., Ren, H., et al. Multiple layer-by-layer lipid-polymer hybrid nanoparticles for improved FOLFIRINOX chemotherapy in pancreatic tumor models. Adv. Funct. Mater. 25 (2015), 788–798.
4. [4] Wang, H., Zhao, Y., Wu, Y., Hu, Y.L., Nan, K., Nie, G., et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32 (2011), 8281–8290.
5. [5] Zhao, X., Li, F., Li, Y., Wang, H., Ren, H., Chen, J., et al. Co-delivery of HIF1alpha siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Biomaterials 46 (2015), 13–25.
6. [6] Wang, H., Wu, Y., Zhao, R., Nie, G., Engineering the assemblies of biomaterial nanocarriers for delivery of multiple theranostic agents with enhanced antitumor efficacy. Adv. Mater. 25 (2013), 1616–1622.
7. [7] Ramos, J., Forcada, J., Hidalgo-Alvarez, R., Cationic polymer nanoparticles and nanogels: from synthesis to biotechnological applications. Chem. Rev. 114 (2014), 367–428.
8. [8] Elsabahy, M., Wooley, K.L., Design of polymeric nanoparticles for biomedical delivery applications. Chem. Soc. Rev. 41 (2012), 2545–2561.
9. [9] Al-Jamal, W.T., Kostarelos, K., Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc. Chem. Res. 44 (2011), 1094–1104.
10. [10] Allen, T.M., Cullis, P.R., Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65 (2013), 36–48.
11. [11] Mitragotri, S., Lahann, J., Materials for drug delivery: innovative solutions to address complex biological hurdles. Adv. Mater. 24 (2012), 3717–3723.
12. [12] Ashley, C.E., Carnes, E.C., Phillips, G.K., Padilla, D., Durfee, P.N., Brown, P.A., et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat. Mater. 10 (2011), 389–397.
13. [13] Malam, Y., Loizidou, M., Seifalian, A.M., Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 30 (2009), 592–599.
14. [14] Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E.S., Baehrecke, E.H., et al. Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ. 16 (2009), 3–11.
15. [15] Taylor, R.C., Cullen, S.P., Martin, S.J., Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 9 (2008), 231–241.
16. [16] Galluzzi, L., Maiuri, M.C., Vitale, I., Zischka, H., Castedo, M., Zitvogel, L., et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 14 (2007), 1237–1243.
17. [17] Kroemer, G., Galluzzi, L., Kepp, O., Zitvogel, L., Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31 (2013), 51–72.
18. [18] Krysko, D.V., Garg, A.D., Kaczmarek, A., Krysko, O., Agostinis, P., Vandenabeele, P., Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12 (2012), 860–875.
19. [19] Casares, N., Pequignot, M.O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202 (2005), 1691–1701.
20. [20] Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D.P., Adam, J., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20 (2014), 1301–1309.
21. [21] Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology, 3, 2014, e955691.
22. [22] Zitvogel, L., Kepp, O., Kroemer, G., Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 8 (2011), 151–160.
23. [23] Galluzzi, L., Senovilla, L., Zitvogel, L., Kroemer, G., The secretally: immunostimulation by anticancer drugs. Nat. Rev. Drug Discov. 11 (2012), 215–233.
24. [24] Denkert, C., Loibl, S., Noske, A., Roller, M., Muller, B.M., Komor, M., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28 (2010), 105–113.
25. [25] DeNardo, D.G., Brennan, D.J., Rexhepaj, E., Ruffell, B., Shiao, S.L., Madden, S.F., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1 (2011), 54–67.
26. [26] Halama, N., Michel, S., Kloor, M., Zoernig, I., Benner, A., Spille, A., et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 71 (2011), 5670–5677.
27. [27] West, N.R., Milne, K., Truong, P.T., Macpherson, N., Nelson, B.H., Watson, P.H., Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res., 13, 2011, R126.
28. [28] Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13 (2007), 1050–1059.
29. [29] Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15 (2009), 1170–1178.
30. [30] Kelland, L.R., Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer 40 (2004), 827–836.
31. [31] Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 30 (2011), 61–69.
32. [32] Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G.M., Apetoh, L., Perfettini, J.L., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13 (2007), 54–61.
33. [33] Vacchelli, E., Ma, Y., Baracco, E.E., Sistigu, A., Enot, D.P., Pietrocola, F., et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 350 (2015), 972–978.
34. [34] Tesniere, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., Ghiringhelli, F., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29 (2010), 482–491.
35. [35] Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71 (2011), 768–778.
36. [36] Ziccheddu, G., Proietti, E., Moschella, F., The Janus face of cyclophosphamide: a sterile inflammatory response that potentiates cancer immunotherapy. Oncoimmunology, 2, 2013, e25789.
37. [37] Spisek, R., Charalambous, A., Mazumder, A., Vesole, D.H., Jagannath, S., Dhodapkar, M.V., Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109 (2007), 4839–4845.
38. [38] Zhao, T., Ren, H., Jia, L., Chen, J., Xin, W., Yan, F., et al. Inhibition of HIF-1alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget 6 (2015), 2250–2262.
39. [39] Andre, T., Tournigand, C., Rosmorduc, O., Provent, S., Maindrault-Goebel, F., Avenin, D., et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann. Oncol. 15 (2004), 1339–1343.
40. [40] Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180 (1994), 83–93.
41. [41] Cosco, D., Bulotta, A., Ventura, M., Celia, C., Calimeri, T., Perri, G., et al. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemother. Pharmacol. 64 (2009), 1009–1020.
42. [42] Rejiba, S., Reddy, L.H., Bigand, C., Parmentier, C., Couvreur, P., Hajri, A., Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine 7 (2011), 841–849.
43. [43] Garg, A.D., Nowis, D., Golab, J., Vandenabeele, P., Krysko, D.V., Agostinis, P., Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim. Biophys. Acta 1805 (2010), 53–71.
44. [44] Garg, A.D., Krysko, D.V., Verfaillie, T., Kaczmarek, A., Ferreira, G.B., Marysael, T., et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 31 (2012), 1062–1079.
45. [45] Kazama, H., Ricci, J.E., Herndon, J.M., Hoppe, G., Green, D.R., Ferguson, T.A., Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29 (2008), 21–32.
46. [46] Luthi, A.U., Cullen, S.P., McNeela, E.A., Duriez, P.J., Afonina, I.S., Sheridan, C., et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31 (2009), 84–98.
47. [47] Soeda, A., Morita-Hoshi, Y., Makiyama, H., Morizane, C., Ueno, H., Ikeda, M., et al. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn. J. Clin. Oncol. 39 (2009), 797–808.
48. [48] Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
49. [49] Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
50. [50] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
51. [51] Royal, R.E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U.S., et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33 (2010), 828–833.
52. [52] Taube, J.M., Klein, A., Brahmer, J.R., Xu, H., Pan, X., Kim, J.H., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20 (2014), 5064–5074.
53. [53] Zheng, L., Xue, J., Jaffee, E.M., Habtezion, A., Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology 144 (2013), 1230–1240.
54. [54] Le, D.T., Lutz, E., Uram, J.N., Sugar, E.A., Onners, B., Solt, S., et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36 (2013), 382–389.